Monitor for the outcome of the Nasdaq Hearings Panel request and any announcement of a strategic transaction (reverse split, capital raise, or M&A) that could restore equity compliance. The company's ability to secure a transaction before the hearing is critical to avoiding delisting.
Price Chart
Executive Summary
Alaunos Therapeutics received a delisting notice from Nasdaq on October 5, 2026, for failing to maintain the minimum $2.5 million stockholders' equity required by Nasdaq Listing Rule 5550(b)(1). The company plans to request a hearing before the Nasdaq Hearings Panel to stay the delisting, and is working with a financial advisor to explore strategic alternatives to regain compliance. The stock faces material delisting risk, which would severely reduce liquidity and institutional ownership.
Key Facts
- Received delisting notice from Nasdaq on October 5, 2026 for non-compliance with Rule 5550(b)(1) requiring minimum $2,500,000 in stockholders' equity
- Company plans to request a hearing before the Nasdaq Hearings Panel to stay suspension or delisting
- Working with a financial advisor to explore strategic alternatives to strengthen financial position and regain compliance
- No assurance that the Panel will grant continued listing or that any strategic transaction will be completed
Financial Impact
Delisting risk with no specific dollar amounts disclosed; stockholders' equity below $2.5M threshold
Risk Factors
- Delisting would severely reduce liquidity and eliminate institutional ownership
- No guarantee the Panel will grant continued listing or an extension period
- Strategic alternatives may not result in a definitive transaction or compliance
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-419154 |
| Document: 0001193125-26-419154-index-headers.html | 0001193125-26-419154 |
| Document: 0001193125-26-419154-index.html | 0001193125-26-419154 |
| Document: 0001193125-26-419154.txt | 0001193125-26-419154 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $2.13 | awaiting T+20 | — | $2.06 (−3.29%) |
Oct 21, 2026 6d ago | 8-K | $3.04 | awaiting T+20 | — | $2.06 (−32.24%) |
Oct 15, 2026 12d ago | SC 13D/A | $2.63 | awaiting T+20 | — | $2.06 (−21.67%) |
Oct 15, 2026 12d ago | SC 13D | $2.63 | awaiting T+20 | — | $2.06 (−21.67%) |
Oct 13, 2026 14d ago | Press Release | $3.03 | awaiting T+20 | — | $2.06 (−32.01%) |
Oct 13, 2026 14d ago | 8-K | $3.03 | awaiting T+20 | — | $2.06 (−32.01%) |
Oct 9, 2026 18d ago | 8-K | $1.05 | awaiting T+20 | — | $2.06 (−96.19%) |
Sep 18, 2026 5w ago | Press Release | $1.20 $2.63 | ▼ −119.17% | ▼ −118.96% | $2.06 (−71.67%) |
Sep 16, 2026 5w ago | 8-K | $1.60 $2.18 | ▲ +36.25% | ▲ +34.79% | $2.06 (+28.75%) |
Jun 29, 2026 17w ago | 8-K | $2.37 $1.94 | ▼ −18.14% | ▼ −17.86% | $2.06 (−13.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers